Vargas-Trujillo C, Álvarez-Rosales H, Molina-Méndez FJ, Rojas-Pérez E, Lespron-Robles MC

Language: Spanish
References: 20
Page: 91-95
PDF size: 67.62 Kb.

ABSTRACT

Dexmedetomidine is a highly specific alpha₂ -agonist with anesthetic, analgesic and sympatholytic properties, capable of dampening the perioperative stress response. We assessed the hemodynamic response to dexmedetomidine and its effects as an adjuvant to anesthesia in the perioperative period. Method: Twenty patients with systemic arterial hypertension undergoing coronary artery bypass grafting were studied. Patients were divided ten each into two groups: Group I, control, and Group II, receiving dexmedetomidine 0.3-05 μg/kg infusion. Statistical analysis was performed by measurements of central tendency and t test. The Ramsay scale was used to assess the degree of sedation. Results: No significant differences were observed among the two groups in heart rate or cardiac output. Systemic blood pressure in the dexmedetomidine group decreased 9% compared with the control group. Systemic vascular resistance decreased 14%, with no hemodynamic impact. Consumption of fentanyl in Group II was 43.1 μg/kg, vs 47.9 μg/kg for the control group. Patients receiving dexmedetomidine tolerated extubation better, maintaining a II-III degree of sedation. Conclusions: Hemodynamic stability is seen at doses of 0.3-0.5 µg/kg/h dexmedetomidine, with no clinical impact. Opioid requirements are reduced, which leads to better tolerance of extubation.

REFERENCES

1. Flacke J, Bloor B, Flacke W. Reduce narcotic requirements by clonidine with improved hemodynamic and adrenergic stability in patients undergoing coronary bypass surgery. Anesthesiology 1987;67:11-9.

2. Engelman E, Gilbart E, Lipszyc M. Effects of clonidine on anesthesic drug requirements and hemodynamic response during aortic surgery. Anesthesiology 1989;71:178-87.

3. Warltier D, Pagel P, Kersten J. Approaches to the prevention of perioperative myocardial ischemia. Anesthesiology 2000;92:253-260.

4. Jaionen J, Hynynen M, Kuitumen A, Heikkila H, Perttila J, Salmenpera M, et al. Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Anesthesiology 1997;86:331-345.

5. Kanabayashi T, Maze M. Clinical uses of alfa2-adrenergic agonist. Anesthesiology 2000;93(5):1345-1349.

6. Takrouri M, Seraj M, Channa A, el-Dawlatly A, Thallage A, Riad W, Khalaf M Middle Esat J Anesthesiol, Dexmedetomidine in intensive care unit: a study of hemodynamic changes. 2002;16(6): 587-95.

7. McCallum J, Boban N, Schmeling W, Kampine J, Bosnjak Z. The mechanism of alpha2-adrenergic inhibition of sympathetic ganglionic transmission. Anesth Analg 1988:87(3):503-10.

8. Talke P, Chen R, Thomas B, Aggarwall A, Gottlieb A, Thorborg P, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery Anesth Analg 2000;90:834-839.

9. Ramsay M, Martin E, Saverage T, Simpson B, Goodwin R. Controlled sedative with alphaxalone-alphadolone. Br Med J 1974;ii: 656-9.

10. Bloor B, Ward D, Belleville J, Maze M. Effects of intravenous dexmedetomidine in humans. II Hemodynamic changes. Anesthesiology 1992;77:1134-1142.

11. Talke P, Li J, Jain U, Leung J, Drasner K, Hollenberg M. et al. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. Anesthesiology 1995;83:620-633.

12. Ferber N, Samso E, Stauton M, et al. Dexmedetomidine modulates cardiovascular responses to stimulation of central nervous systems pressor sites. Anesth Analg 1999;88(3)617-24.

13. Belleville J, Ward D, Bloor B, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992;77:1125-1133.

14. Hall J, Uhrich T, Barney J Arain S, Ebert T Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth. Analg 2000;90(3):699-705.

15. Venn M, Hell J, Grounds R. Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care. Crit Care 2000;4(5):302-8.

16. Venn M, Newmann J, Grounds M. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003;29(2):201-7.

17. Nelson L, Lu J, Guo T, Saper C, Franks N, Maze M. The alpha 2 adrenoceptor agonist dexmedetomidine converges on an endogenous sleep promoting pathway to exert its sedative effects. Anesthesiology 2003;98(2):428-36.

18. Hougue Jr, Talke P, Stein P, Richardson C, Domitrovich, Sessler D. Autonomic nervous system responses during sedative infusions of dexmedetomidine 2002;97(3):59-8.

19. Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg 2002;95;461-46.

20. McPherson RW, Koehler RC, Kirsch JR, Traystman RJ. Intravascular dexmedetomidine decreases cerebral blood flow during normoxia and hypoxia in dogs. Anesth Analg 1997;84: 139-47.